Showing results (71-80 of 241) with videos related to
Sort By:
Pageof 25
Gynecologic Oncology|July 1, 2017
Improved survival with definitive chemoradiation compared to definitive radiation alone in squamous cell carcinoma of the vulva: A review of the National Cancer DatabaseYuan James Rao, Re-I Chin, Caressa Hui, et al.Gynecologic Oncology|January 25, 2015
Impact of an immunohistochemistry-based universal screening protocol for Lynch syndrome in endometrial cancer on genetic counseling and testingAntonina I Frolova, Sheri A Babb, Emily Zantow, et al.Gynecologic Oncology|October 22, 2008
Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancerRebecca A Brooks, Janet S Rader, Farrokh Dehdashti, et al.Gynecologic Oncology|January 21, 2025
Not all uterine carcinosarcomas are created equal: Survival outcomes according to molecular characterization of uterine carcinosarcomaMichael D Toboni, Kaitlyn Dinkins, Sharon Wu, et al.Gynecologic Oncology|August 4, 2019
Risk of cervical and vaginal dysplasia after surgery for vulvar intraepithelial neoplasia or cancer: A 6 year follow-up studyTommy R Buchanan, Abigail S Zamorano, Leslie S Massad, et al.Gynecologic Oncology|August 1, 2006
Colposcopic accuracy of obstetrics and gynecology residentsMargaret E Baum, Janet S Rader, Randall K Gibb, et al.Journal of the National Cancer Institute|March 30, 2013
Disparities in ovarian cancer care quality and survival according to race and socioeconomic statusRobert E Bristow, Matthew A Powell, Noor Al-Hammadi, et al.International Journal of Radiation Oncology, Biology, Physics|October 14, 2015
Brachytherapy Is Associated With Improved Survival in Inoperable Stage I Endometrial Adenocarcinoma: A Population-Based AnalysisSahaja Acharya, Stephanie M Perkins, Todd DeWees, et al.Gynecologic Oncology|December 3, 2014
Ovarian cancer in the United States: contemporary patterns of care associated with improved survivalWilliam A Cliby, Matthew A Powell, Noor Al-Hammadi, et al.Oncotarget|April 28, 2016
Mesothelin's minimal MUC16 binding moiety converts TR3 into a potent cancer therapeutic via hierarchical binding events at the plasma membraneYang Su, Katharina Tatzel, Xuejun Wang, et al.Pageof 25